TwistTwist rolls out TCR and CAR libraries for cell therapies development
18 Apr 2023
Cell TherapyClinical StudyGene Therapy
Preview
Source: Pharmaceutical Technology
The TCR and CAR libraries will help researchers develop new cell therapies. Credit: Anusorn Nakdee via Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Twist Bioscience has introduced Twist T-cell receptor (TCR) and Twist chimeric antigen receptor (CAR) libraries to facilitate the development of cell therapies.
Researchers will now be able to speed up the creation of tailor-made libraries that can help in identifying and developing new cell therapies.
Both libraries feature up to 10,000 gene fragment combinations, and allow the high-throughput screening and characterisation of new and known sequence variants to develop therapeutic solutions.
The libraries include combinations of tailor-made gene parts that are shuffled to help customers test various elements instantly, as well as to discover new combinations of variable binding regions and choose candidates with therapeutic potential.
This will speed up the discovery stage and accelerate the timeline for the clinic.
Twist Bioscience CEO and co-founder Emily Leproust said: “With the dramatic increase in interest around cell and gene therapies, the addition of Twist CAR and TCR Libraries offers an important and differentiated tool to enable the development of the next generation of treatments for those suffering from a wide range of diseases.
“Twist CAR and TCR Libraries allow researchers and drug developers to fine-tune these receptors to address the challenges of cell therapies, including off-target toxicity, enabling rapid advancement toward the clinic.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.